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Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is best known for promoting atherosclerosis.
In this issue of Immunity, Joo et al. (2014) find that dendritic cells triggered through LOX-1 can directly sup-
port plasmablast production via the production of the cytokines APRIL and BAFF.Lectin-like oxidized low-density lipoprotein
receptor-1 (LOX-1) is one of the seven
members of the ‘‘Dectin-1 cluster’’ located
within thenatural killergene (NKG)complex
on human chromosome 12 (mouse chro-
mosome 6) (Huysamen and Brown, 2009).
While the other members of this cluster
of C-type lectin-like receptors, which
includes MICL (CLEC12A), DNGR1
(CLEC9A), and Dectin-1 (CLEC7A), are pri-
marily expressed on myeloid cells, LOX-1
(CLEC8A) is expressed on endothelial and
smoothmuscle cells, platelets, fibroblasts,
and B cells, as well as macrophages and
dendritic cells (DCs) (Huysamen and
Brown, 2009; Joo et al., 2014). LOX-1 is
also differentiated from the other members
of Dectin-1 cluster by the fact that it is one
of themanydifferent typesof scavenger re-
ceptors that are capable of binding to
oxidized low-density lipoproteins (oxLDL),
as well as a range of other endogenous
and exogenous ligands. The recognition
of oxLDL by LOX-1 expressed on vascular
endothelial cells appears to play a signifi-
cant role in the development of atheroscle-
rosis (Mehta et al., 2007). However, the
expression of LOX-1 on macrophages
and DCs coupled with its ability to bind a
range of ligands including gram-negative
and gram-positive bacteria, have sug-
gested that it might also play a role as
an immunomodulatory pattern-recognition
receptor similar to the other members of
the Dectin-1 cluster. Indeed, as with
adjuvant strategies involving MICL and
CLEC9A, targeting of antigen to LOX-1
with antibody conjugates is an effective
technique for enhancing antigen-specific
immunity (CaminschiandShortman,2012).
Targeting of antigen to DCs is typically
used to establish strong CD8+ or CD4+
T cell responses, taking advantage of the
fact that DCs are efficient at presenting
peptide antigens with both class I andclass II MHCs and are strong sources of
costimulatory ligands. The role of DCs in
stimulating humoral immunity is primarily
thought to be mediated via the activation
of CD4+ cells, such as the strong induction
of T follicular helper cells that occurs in
response to antigens targeted viaCLEC9A
(Caminschi and Shortman, 2012). How-
ever, there is a significant bodyof evidence
that DCs can also promote antibody re-
sponses through direct interactions with
B cells. For example, it is well established
that DCs can be potent sources of the B
cell stimulatory and survival factors BAFF
and APRIL and can thus directly induce
class switchingandplasmablastdifferenti-
ation (MacLennan and Vinuesa, 2002). In
addition, DCs have been shown to harbor
intact antigen on their cell surface (Qi
et al., 2006), indicating that they have the
capacity to stimulate B cells through both
the B cell receptor (BCR) and accessory
receptors. Nevertheless, the contribution
of direct activation of B cells and plasma-
blasts by DCs during in vivo humoral re-
sponses is unclear and requires further
elucidation of how DCs might coordinate
the signals they deliver to B-lineage cells.
In this issue of Immunity, Joo et al.,
(2014) examined the possibility that trig-
gering of LOX-1 on immune cells might
play a role directly stimulating antibody
production byBcells. As a first step, amu-
rinemonoclonal antibody directed against
human LOX-1 was generated. Staining
of human PBMCs with this antibody re-
vealed cell surface expression of LOX-1
on DCs, monocytes, and B cells, but
not on T cells. To examine LOX-1 function
on human DCs, the authors derived
DCs from interleukin-4 (IL-4) + GM-CSF
cultured CD14+ blood monocytes and
then incubated them with the anti-LOX-1
mAb. In contrast to DCs incubated with
control antibody, those stimulated viaImmunity 41LOX-1 were found to be strong inducers
of the proliferation and plasmablast differ-
entiation of human blood CD19+ B cells.
Secretion of high levels of immunoglobulin
M (IgM), IgG, and IgA antibodies was
observed in cultures with LOX-1-stimu-
lated DCs, as was the induction of Ig
class switching. Plasmablasts generated
in these cultures showed the upregulation
of CCR10 and downregulation of CXCR5
expression typically associated with
plasmablast differentiation, as well as
increased chemotaxis to the CCR10
ligands CCL27 and CCL28. Although B
cells themselves did express LOX-1,
direct stimulation of B cells with the LOX-
1 mAb did not trigger appreciable B
cell proliferation or differentiation. It did,
however, lead to increased expression of
CCR7 and CCL19-mediated chemotaxis
by B cells, suggesting that direct stimula-
tion of B cells by LOX-1 ligands might
modify their migration in vivo.
So what is it about LOX-1 stimulated
DCs that allows them to support B cell
proliferation and differentiation? Stimula-
tion of DCs via LOX-1 was found by Joo
et al. to trigger the production of the tumor
necrosis factor (TNF) superfamily ligands
BAFF and APRIL (Joo et al., 2014). Block-
ing studies verified that the stimulation of
B cells by LOX-1 stimulated DCs occurred
primarily via the actions of these ligands,
APRIL being particularly important for the
production of IgM and IgA antibodies
and BAFF for the production of IgG.
When a series of alternative anti-LOX-1
mAbswere tested for their ability to trigger
APRIL and BAFF production by DCs, they
were all found to be inferior to the clone
(8B4) produced by the authors. Moreover,
mAbs directed against a range of other
DC-expressed pattern-recognition recep-
tors (DC-SIGN, Dectin-1, DCIR, DEC205)
triggered little or no BAFF and/or APRIL, October 16, 2014 ª2014 Elsevier Inc. 507
Figure 1. Potential Scenarios for LOX-1-Mediated Augmentation of Humoral Immunity by
Extrafollicular Dendritic Cells
(Left) Antigen-activated B cell blasts are expanded in either a T-dependent or T-independent manner near
the follicular-T cell zone boundary. T helper (Th) cells can drive the differentiation of germinal center B cells,
whereas both T-independent and T-dependent responses can drive migration of B cell blasts to the
DC-rich extrafollicular regions of the secondary lymphoid tissues. Here, B cell blasts can differentiate
into either switched or unswitched plasmablasts, potentially influenced by signals from extrafollicular
Th cells, as well as DCs.
(Right) Extrafollicular B cells could receive stimulatory signals from LOX-1-activatedDCs in the formof BAFF
and/or APRIL in either protective or autoimmune antibody responses. Thus, LOX-1 on DCs can be triggered
by structures on foreignbacteria and, potentially in conjunctionwith foreignantigenpresentedon theDCsur-
face,driveBcellproliferationanddifferentiation.On theotherhand,LOX-1mightbe triggeredbyendogenous
ligands, suchasoxLDLs, and self-reactiveBcells therefore triggeredwith resultingautoantibodyproduction.
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question of whether the rare ability of the
8B4 anti-LOX-1 clone to activate the B
cell stimulatory activity of DCs was simply
a quirk of this mAb clone or did in fact
reflect a physiologically relevant activity
of LOX-1? To answer this question, Joo
et al. utilized one of the natural ligands of
LOX-1, oxLDL, to trigger DCs. DCs incu-
bated with oxLDL were found to produce
BAFF and APRIL and to have B cell stimu-
latory properties that were indistinguish-
able from those stimulated with 8B4.
The findings of Joo et al. indicate that
LOX-1 joins the receptors for interferon-a
(IFN-a), IFN-g, andCD40 ligand asDC sur-
face molecules capable of triggering the
production of BAFF and/or APRIL by DCs
(Joo et al., 2014; Litinskiy et al., 2002).
The potential for DCs to support B cell re-
sponseswhen triggered in this way is clear
and demonstrable in vitro. Whether DCs
impact humoral immunity in thisway in vivo
and under what circumstances this might
occur is more difficult to determine. A link
between DCs and plasmablast survival
and differentiation in vivo has long been
suspected due to the fact that activated B
cells undergoing plasmablast differentia-
tion in response to either T-dependent or
T-independent antigens migrate extrafol-508 Immunity 41, October 16, 2014 ª2014 Ellicularly to areas rich in CD11c+ DCs within
secondary lymphoid tissues (Figure 1).
Similarly, plasmablasts generated in an
autoimmune setting colocalize with DCs,
and there is some evidence that DCs
support autoreactive plasmablasts in vivo
under these circumstances (Teichmann
et al., 2010). Given that DCs can present
intact antigen to B cells (Qi et al., 2006)
and that BCR triggering synergizes with
the BAFF and APRIL signals delivered by
DCs (Litinskiy et al., 2002), onecan imagine
that DCs might well be a significant driver
of plasmablast responses to both foreign
and self-antigens.While this might happen
in the absence of T cell signals (Litinskiy
et al., 2002), extrafollicular T helper cells
havealsobeendescribed that have thepo-
tential to collaborate with DCs in support-
ingplasmablast proliferationanddifferenti-
ation in response to T-dependent antigen
(Chan et al., 2009; Odegard et al., 2008).
How then could triggering of LOX-1 on
DCs play a role in in vivo B cell responses?
In addition to oxLDL, LOX-1 recognizes a
range of other endogenous ligands asso-
ciated with inflammation (Huysamen and
Brown, 2009). Thus, similar to its role
on endothelial cells, DC-expressed LOX-1
might act as an inflammatory sensor, in
this case facilitating the support of re-sevier Inc.sponding B cells through BAFF and APRIL
production potentially in conjunction with
presentation of intact antigen (Figure 1).
Clearly, the LOX-1-mediated triggering of
DCs by ligands associated with inflamma-
tion has the potential to support B cells
in both protective and autoimmune re-
sponses (Figure 1). However, the ability of
LOX-1 to bind both gram-positive and
gram-negative bacteria raises the possibil-
ity that DCs could provide a direct support
to B cell responses under circumstances
where rapid production of antibodies is
required to combat replicative pathogens
(Figure 1). In the case of T-dependent anti-
gens, LOX-1-activatedDCsmight collabo-
rate with extrafollicular T helper cells to
enhance humoral responses. Ultimately,
precise determination of the role of DC-ex-
pressed LOX-1 will require sophisticated,
cell-specific gene inactivation studies
in mice. Nevertheless, the studies of Joo
et al. provide a valuable insight into the
functional capabilities of DC-expressed
LOX-1 in the human context and suggest
that it is worth considering as a target
molecule in vaccines designed to promote
humoral immune responses.REFERENCES
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